CAMBRIDGE, Mass., Feb. 28 /PRNewswire/ -- GENETIX Pharmaceuticals Inc. announced today that James A. Geraghty has joined the Company's Board of Directors. Mr. Geraghty is Senior Vice President of Genzyme Corporation and head of its cardiovascular business. At Genzyme, he was previously Senior Vice President of International Development and President of Genzyme Europe. He is a founder, former Chairman, and member of the Board of GTC Biotherapeutics.
"Jim Geraghty is a respected pharmaceutical executive with experience developing global markets for high-value products in specialized indications, similar to GENETIX' lead product LentiGlobin(TM) hemoglobin gene therapy for sickle cell disease and thalassemia major," said Stephen J. Hoffman, Chairman of the Board of Directors of GENETIX and General Partner with TVM Techno Venture Management. "His expertise will be ideal for the GENETIX Board."
Mr. Geraghty is a graduate of Georgetown University and the Yale Law School. Prior to joining Genzyme in 1992, he was a senior management consultant with Bain and Company where he served Fortune 100 clients in the pharmaceutical and medical device industries. He currently serves as a member of the Board of Directors of Myosix, SA in Paris and of the Advisory Board of KBC Biotech Fund in Belgium.
"GENETIX has the potential to make a major contribution to the health of sickle cell and thalassemia patients," said Mr. Geraghty. "I look forward to working with its very dedicated team to try to help make this potential a reality." "Jim has made outstanding contributions as a member of the GENZYME management team over the past decade, and I am excited to have him join our Board and look forward to working with him," said Walter Ogier, President and Chief Executive Officer of GENETIX Pharmaceuticals.
GENETIX Pharmaceuticals, Inc. is a privately held, development stage company located in Cambridge, Massachusetts and founded by researchers affiliated with the Massachusetts Institute of Technology, Harvard and Columbia Universities. The Company's LentiGlobin(TM) hemoglobin gene therapy utilizes a modified human lentivirus to deliver a corrective version of the beta-globin gene to the chromosomes of blood stem cells. The approach has resulted in lifetime correction of all clinical symptoms of sickle cell disease and thalassemia major in animal models, following a single gene therapy treatment. The Company holds numerous patents covering lentiviral vectors for gene therapy, anti-sickling forms of beta-globin, and red blood cell-specific gene expression. Additional information is available at the Company's website, http://www.genetixpharm.com/.
GENETIX Pharmaceuticals Inc.
CONTACT: Walter C. Ogier, President and Chief Executive Officer, +1-617-873-0752, email@example.com, or Ronald C. Dorazio, MD, Vice PresidentCorporate Development, +1-617-873-0903, firstname.lastname@example.org both ofGENETIX Pharmaceuticals, Inc.